G V Krepart
Overview
Explore the profile of G V Krepart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
104
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Le T, Adolph A, Krepart G, Lotocki R, Heywood M
Gynecol Oncol
. 2002 Apr;
85(2):351-5.
PMID: 11972399
Objective: The management of understaged patients with apparent clinically early ovarian cancer is difficult. Options include offering chemotherapy based on histopathologic factors or reoperation to obtain the necessary information needed...
2.
Baral E, Nagy E, Krepart G, Lotocki R, Unruh H, Berczi I
Anticancer Res
. 2000 Aug;
20(3B):2027-31.
PMID: 10928146
Background: The antiestrogens tamoxifen (TX) and toremifene (TO) were shown previously to enhance the lysis of target cells by natural killer cells (NK), lymphokine activated killer (LAK) cells, and by...
3.
Le T, Krepart G, Lotocki R, Heywood M
Gynecol Oncol
. 1999 Jul;
74(2):252-4.
PMID: 10419740
Objectives: The role of adjuvant therapy in patients with early stage ovarian carcinoma has not been clearly defined. Most randomized trials examining this issue have not used the vigorous staging...
4.
Le T, Krepart G, Lotocki R, Heywood M
Gynecol Oncol
. 1997 Dec;
67(2):208-14.
PMID: 9367710
Aggressive tumor reduction surgery has been widely used in patients with advanced stage epithelial ovarian carcinoma before initiation of cytotoxic chemotherapy. No randomized controlled trial has been carried out to...
5.
Le T, Krepart G, Lotocki R, Heywood M
Gynecol Oncol
. 1997 May;
65(2):237-40.
PMID: 9159331
Mixed mesodermal sarcoma of the ovary is a rare clinical entity. To review the epidemiology, prognostic factors, and treatment results related to primary ovarian sarcoma at our center, a retrospective...
6.
Stuart G, Krepart G, Drouin P, PARASKEVAS M
CMAJ
. 1996 Oct;
155(8):1037.
PMID: 8873624
No abstract available.
7.
Faught W, Lotocki R, Heywood M, Krepart G
Eur J Gynaecol Oncol
. 1996 Jan;
17(3):200-3.
PMID: 8780918
Objective: To assess the risk of recurrence in patients with stage I (negative cytology) epithelial ovarian cancer receiving no adjuvant therapy. Methods: Between 1976 and 1991, 51 patients with apparent...
8.
Faught W, Kirkpatrick J, Krepart G, Heywood M, Lotocki R
J Am Coll Surg
. 1995 Apr;
180(4):472-4.
PMID: 7536598
Background: Ascites is a common sequela of advanced or recurrent gynecologic malignancies, such as carcinoma of the ovary, fallopian tube, or endometrium. Symptomatic treatment with repeated paracentesis is the initial...
9.
Faught W, Krepart G, Lotocki R, Heywood M
Gynecol Oncol
. 1994 Oct;
55(1):51-5.
PMID: 7959266
Surgical staging of adenocarcinoma of the endometrium attempts to identify the true distribution of disease. The survival value of paraaortic lymphadenectomy selectively performed in patients with histologic risk factors is...
10.
Lotocki R, Krepart G, PARASKEVAS M, Vadas G, Heywood M, Fung F
Gynecol Oncol
. 1992 Mar;
44(3):254-9.
PMID: 1541437
Glassy cell carcinoma of the cervix is a distinct clinicopathologic entity. This infrequent pathologic subtype is an aggressive biologic tumor associated with a rapid clinical course and poor outcome with...